News! China's first targeted CD30 antibody drug adjuvant ADCETRIS (brentuximab vedotin) approved
-
Last Update: 2020-05-29
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Takeda China announced today that The ADuximab vedotin, which targets CD30, has been officially approved by the State Drug Administration (NMPA) for the treatment of patients with recurrent or incurable systemic degenerative large cell lymphoma (sALC) or CD30-positive Hodgkin's lymphoma"We expect that Brentuximab vedotin will provide better treatment options for CD30-positive lymphoma patients in China," said Professor Jun Zhu, lead researcher in theChina's ADCETRIS Registered StudyBoth sALCL and classic Hodgkin's lymphoma are subtypes of lymphoma that express CD30For decades, patients with recurrent or refractory lymphoma in China have had very limited treatment optionsThe total survival rate of patients is low and the quality of life is poor"lymphoma is a malignant tumor that originates from the lymphoma system and is the general name of more than 70 subtypes in the lymphoma familyIt is one of the top ten malignant tumors with the highest mortality rate in ChinaIn China, about 93,000 people are diagnosed with lymphoma each year, and more than 50,000 of them die as a result, according to the dataCurrently, treatment for recurrent or refractory lymphoma patients in China is very limited
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
